This clinical trial is focused on studying treatments for urothelial cancer, which is a type of cancer that affects the bladder and other parts of the urinary system. The study will explore the effectiveness of a new treatment called BT8009, both on its own and in combination with other medications. These medications include pembrolizumab, cisplatin, carboplatin, gemcitabine, and avelumab. The purpose of the study is to see how well these treatments work in slowing down the progression of the cancer or in reducing the size of the tumors.
Participants in the study will be divided into different groups. Some will receive BT8009 alone, while others will receive it in combination with pembrolizumab. Another group will receive a combination of chemotherapy drugs, which may include cisplatin or carboplatin with gemcitabine, and possibly avelumab as a maintenance treatment. The study will monitor the participants over a period of time to assess the effectiveness of these treatments in managing the cancer.
The trial aims to provide valuable information on how these treatments can help patients with advanced stages of urothelial cancer. By comparing the different treatment options, researchers hope to find the most effective approach to improve the outcomes for patients with this type of cancer. Participants will receive regular assessments to track the progress of their treatment and any changes in their condition.
Austria 
Belgium 
Bulgaria 
Czechia 
Denmark 
France 
Germany 
Greece 
Hungary 
Ireland 
Italy 
Latvia 
Norway 
Poland 
Portugal 
Romania 
Spain 
The Netherlands